Source comparison
Comparison: Thymosin Alpha-1 Dosage Protocols Across Research Applications
Immune function baseline studies 1.6 mg (0.023 mg/kg) Twice weekly 4–12 weeks Standard protocol for healthy subjects; well-tolerated with minimal adverse events reported in trials Chronic viral infection models 1.6–3.2 mg 12–24 weeks Higher doses used in hepat
This comparison does not assign a generated winner or score.
- Immune function baseline studies
- 1.6 mg (0.023 mg/kg)
- Twice weekly
- 4–12 weeks
- Standard protocol for healthy subjects; well-tolerated with minimal adverse events reported in trials
- Chronic viral infection models
- 1.6–3.2 mg
- 12–24 weeks
- Higher doses used in hepatitis B/C studies published in Journal of Viral Hepatology; dose escalation linked to CD4+ response
- Cancer immunotherapy adjunct
- 3.2 mg
- 8–16 weeks during chemotherapy
- Upper therapeutic range; used in oncology trials to counter chemotherapy-induced immunosuppression
- Post-surgical immune recovery
- 1.6 mg
- 4–8 weeks post-op
- Short-duration protocol; endpoints typically measure surgical site infection rates and lymphocyte recovery
- Vaccine response enhancement
- Twice weekly starting 1 week pre-vaccination
- 3–4 weeks total
- Timing relative to antigen exposure matters—pre-treatment primes immune response more effectively than post-vaccination dosing
- The table shows dose consistency across most applications (1.6 mg as the anchor dose) with escalation reserved for severe immune compromise. Frequency remains twice weekly regardless of indication, reflecting the peptide's pharmacokinetic profile. When reviewing protocols to calculate Thymosin Alpha-1 dosage for your specific research application, match your endpoint (immune cell counts, viral load, infection rates) to published studies using similar doses rather than extrapolating from unrelated therapeutic areas.